Company intelligence / Profile preview

Aprea Therapeutics

Doylestown, Pennsylvania, United Statesir.aprea.com ↗

Ownership: Public · APRE
Development stage: Phase 1

Overview

Currently conducting Phase 1 ACESOT-1051 trial for WEE1 inhibitor APR-1051 with preliminary results showing good tolerability. Also advancing Phase 1/2a ABOYA-119 study for ATRN-119, a macrocyclic ATR inhibitor, with twice-daily dosing regimen implemented to optimize clinical outcomes[9][6].

Therapeutic areas: Oncology
Modalities: Small moleculesMacrocyclic inhibitors
Industry: Biotech

Drug pipeline

9 assets

ATRN-119

8 more assets in the full pipeline.

Request access →

Financials

Market cap: $9.8M
Total revenue: $0
Enterprise value: $-31.4M

Beyond the preview

Go deeper on Aprea Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aprea Therapeutics.

Explore the full profile